Evaluating the timing of cancer treatment after COVID-19 infection
When to Initiation Antitumor Therapy for Tumor Patients With COVID19 Infection
This study is trying to see if starting cancer treatment soon after recovering from COVID-19 is safe and how it affects patients' quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | The Seventh Affiliated Hospital of Sun Yat-sen University Academic / other |
| Locations | 1 site (Shenzhen, Guangdong) |
| Trial ID | NCT06006845 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the safety of starting antitumor therapy in patients who have recently recovered from COVID-19, as indicated by a negative nucleic acid test. It will investigate whether early initiation of treatment increases adverse events or the risk of COVID-19 re-infection, as well as its impact on the quality of life of these patients. Participants will provide information on their COVID-19 symptoms, diagnosis dates, and quality of life before and during their infection.
Who should consider this trial
Good fit: Ideal candidates include tumor patients who have been diagnosed with COVID-19 and have received systemic antitumor therapy after their infection.
Not a fit: Patients who have not confirmed their COVID-19 infection through testing or who have not received systemic antitumor therapy will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help determine safe timelines for resuming cancer treatments in patients recovering from COVID-19.
How similar studies have performed: While there may be limited data on this specific approach, similar studies have explored the timing of cancer treatments during viral infections, indicating potential for valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Tumor patients diagnosed with COVID-19 infection at our center from December 1, 2022 to May 31. * COVID-19 was confirmed by antigen testing or nucleic acid testing. * Tumor was confirmed by pathology. * Patients received systemic antitumor therapy after infected with COVID-19. Exclusion Criteria: * COVID-19 was not confirmed by antigen testing or nucleic acid testing * Tumor was not confirmed by pathology * Patients did not receive systemic antitumor therapy * Patients died before receiving systemic antitumor therapy
Where this trial is running
Shenzhen, Guangdong
- Seventh Affiliated Hospital, Sun Yat-sen University — Shenzhen, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: Bo Wang — The Seventh Affiliated Hospital of Sun Yat-sen University
- Study coordinator: Xiaofen Pan, MD
- Email: panxf8@mail.sysu.edu.cn
- Phone: +8618124671750
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.